Insulinoma: approaches to diagnosis and treatment

Main Article Content

M.A. Zaitsev

Abstract

A review of the literature deals with the most common functioning neuroendocrine tumor of β-cells of the islets of Langerhans of the pancreas, which is characterized by uncontrolled insulin production. Pathophysiological basis of clinical manifestations of tumors from β-cells of the islets of Langerhans are due to the hormonal activity of these tumors. In the absence of subordination to the physiological mechanisms that regulate glucose homeostasis, β-cell adenomas lead to the development of chronic hypoglycemia. Taking into consideration that the symptoms of insulinoma occur due to hyperinsulinemia and hypoglycemia, the severity of clinical manifestations of the disease in each case indicates the individual sensitivity of the patient to insulin and low blood sugar. The vast majority of insulin-producing tumors of the pancreas have a size that does not exceed 0.5–2 cm in diameter, which makes it difficult to detect them during surgery. Thus, in 20 % of patients with the first, and sometimes with the second and third operations, it is not possible to detect tumor. Malignant insulinomas occur in 10–15 % of cases, and a third of them metastasize. The only radical treatment for insulinoma is surgery. Conservative treatments are used only in inoperable patients, as well as the means that temporarily eliminate hypoglycemia and are used to prepare the patient for surgical treatment. It is emphasized that the successful treatment of patients with endogenous hyperinsulinism requires a comprehensive team approach, which includes the use of modern imaging techniques and high-tech treatments.

Article Details

How to Cite
Zaitsev, M. “Insulinoma: Approaches to Diagnosis and Treatment”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 16, no. 7, Mar. 2021, pp. 588-92, doi:10.22141/2224-0721.16.7.2020.219013.
Section
Literature Review

References

Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):753-81. doi: 0.1016/j.bpg.2005.06.002.

Chang F, Chandra A, Culora G, Mahadeva U, Meenan J, Herbert A. Cytologic diagnosis of pancreatic endocrine tumors by endoscopic ultrasound-guided fine-needle aspiration: a review. Diagn Cytopathol. 2006 Sep;34(9):649-58. doi:10.1002/dc.20503.

Khacimova LS, Karonova TL, Tsoy UA, Ianevskaia LG, Grineva EN. Insulinoma: diagnostic features and treatment management. Problems of Endocrinology. 2017;63(4):212-218. doi:10.14341/probl2017634212-218. (in Russian).

Chang F, Chandra A, Culora G, Mahadeva U, Meenan J, Herbert A. Cytologic diagnosis of pancreatic endocrine tumors by endoscopic ultrasound-guided fine-needle aspiration: a review. Diagn Cytopathol. 2006 Sep;34(9):649-58. doi:10.1002/dc.20503.

Sotoudehmanesh R, Hedayat A, Shirazian N, et al. Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine. 2007 Jun;31(3):238-41. doi:10.1007/s12020-007-0045-4.

Oberg K. Pancreatic endocrine tumors. Semin Oncol. 2010 Dec;37(6):594-618. doi:10.1053/j.seminoncol.2010.10.014.

Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008 Nov;135(5):1469-92. doi:10.1053/j.gastro.2008.05.047.

Vanderveen K, Grant C. Insulinoma. Cancer Treat Res. 2010;153:235-52. doi:10.1007/978-1-4419-0857-5_13.

Guettier JM, Gorden P. Insulin secretion and insulin-producing tumors. Expert Rev Endocrinol Metab. 2010 Mar 1;5(2):217-227. doi:10.1586/eem.09.83.

de Herder WW, Niederle B, Scoazec JY, et al; Frascati Consensus Conference; European Neuroendocrine Tumor Society. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology. 2006;84(3):183-8. doi:10.1159/000098010.

Zhao YP, Zhan HX, Zhang TP, et al. Surgical management of patients with insulinomas: Result of 292 cases in a single institution. J Surg Oncol. 2011 Feb;103(2):169-74. doi:10.1002/jso.21773.

de Herder WW, Niederle B, Scoazec JY, et al; Frascati Consensus Conference; European Neuroendocrine Tumor Society. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology. 2006;84(3):183-8. doi:10.1159/000098010.

Mathur A, Gorden P, Libutti SK. Insulinoma. Surg Clin North Am. 2009 Oct;89(5):1105-21. doi:10.1016/j.suc.2009.06.009.

Marsk R, Jonas E, Rasmussen F, Näslund E. Nationwide cohort study of post-gastric bypass hypoglycaemia including 5,040 patients undergoing surgery for obesity in 1986-2006 in Sweden. Diabetologia. 2010 Nov;53(11):2307-11. doi:10.1007/s00125-010-1798-5.

Patti ME, Goldfine AB. Hypoglycaemia following gastric bypass surgery--diabetes remission in the extreme? Diabetologia. 2010 Nov;53(11):2276-9. doi:10.1007/s00125-010-1884-8.

Kulke MH, Anthony LB, Bushnell DL, et al; North American Neuroendocrine Tumor Society (NANETS). NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010 Aug;39(6):735-52. doi:10.1097/MPA.0b013e3181ebb168.

Cryer PE, Axelrod L, Grossman AB, et al; Endocrine Society. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009 Mar;94(3):709-28. doi:10.1210/jc.2008-1410.

Jensen RT, Cadiot G, Brandi ML, et al; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95(2):98-119. doi:10.1159/000335591.

Vinik AI, Woltering EA, Warner RR, et al; North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010 Aug;39(6):713-34. doi:10.1097/MPA.0b013e3181ebaffd.

Kandaswamy L, Raghavan R, Pappachan JM. Spontaneous hypoglycemia: diagnostic evaluation and management. Endocrine. 2016 Jul;53(1):47-57. doi:10.1007/s12020-016-0902-0.

Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol. 2010 Feb;6(2):229-37. doi:10.2217/fon.09.165.

Eloubeidi MA, Decker GA, Chandrasekhara V, et al; ASGE Standards of Practice Committee. The role of endoscopy in the evaluation and management of patients with solid pancreatic neoplasia. Gastrointest Endosc. 2016 Jan;83(1):17-28. doi:10.1016/j.gie.2015.09.009.

Luo Y, Pan Q, Yao S, et al. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study. J Nucl Med. 2016 May;57(5):715-20. doi:10.2967/jnumed.115.167445.

Falconi M, Eriksson B, Kaltsas G, et al; Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103(2):153-71. doi:10.1159/000443171.

Câmara-de-Souza AB, Toyoshima MTK, Giannella ML, et al. Insulinoma: A retrospective study analyzing the differences between benign and malignant tumors. Pancreatology. 2018 Apr;18(3):298-303. doi:10.1016/j.pan.2018.01.009.

Kunz PL, Reidy-Lagunes D, Anthony LB, et al; North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May;42(4):557-77. doi:10.1097/MPA.0b013e31828e34a4.

Liang M, Jiang J, Dai H, et al. Robotic enucleation for pediatric insulinoma with MEN1 syndrome: a case report and literature review. BMC Surg. 2018 Jun 19;18(1):44. doi:10.1186/s12893-018-0376-5.

Belfiori G, Wiese D, Partelli S, et al. Minimally Invasive Versus Open Treatment for Benign Sporadic Insulinoma Comparison of Short-Term and Long-Term Outcomes. World J Surg. 2018 Oct;42(10):3223-3230. doi:10.1007/s00268-018-4628-4.

Dąbkowski K, Gajewska P, Walter K, et al. Successful EUS-guided ethanol ablation of insulinoma, four-year follow-up. Case report and literature review. Endokrynol Pol. 2017;68(4):472-479. doi:10.5603/EP.2017.0053.

Mujica-Mota R, Varley-Campbell J, Tikhonova I, et al. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2018 Sep;22(49):1-326. doi:10.3310/hta22490.